KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Liabilities for 13 consecutive years, with $51.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 18.89% to $51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.4 million through Dec 2025, up 18.89% year-over-year, with the annual reading at $51.4 million for FY2025, 18.89% up from the prior year.
  • Total Liabilities for Q4 2025 was $51.4 million at Xenon Pharmaceuticals, up from $48.3 million in the prior quarter.
  • The five-year high for Total Liabilities was $51.4 million in Q4 2025, with the low at $14.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $31.9 million, with a median of $33.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities plummeted 70.66% in 2021, then soared 103.16% in 2023.
  • Over 5 years, Total Liabilities stood at $22.0 million in 2021, then soared by 48.58% to $32.6 million in 2022, then increased by 12.95% to $36.9 million in 2023, then grew by 17.24% to $43.2 million in 2024, then grew by 18.89% to $51.4 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $51.4 million, $48.3 million, and $40.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.